Rss Feed

Brigham researchers' findings from next-generation sequencing suggest that revising current cancer care guidelines could allow approximately 6,000 more patients in the U.S. to benefit from immunotherapy treatment each year

Very early in the COVID-19 pandemic clinical trials in patients hospitalized with COVID-19 confirmed that corticosteroids like dexamethasone reduced mortality, but they were harmful when applied at the first COVID-19 symptoms, due to the weakening of innate antiviral immunity, leading to delayed viral clearance and adverse outcomes in severe viral pneumonias.